

U.S. Serial No. 09/599,213

Claims 14 and 15 have been amended and are as follows:

- C<sup>2</sup>
- 13/14. (Amended) The method of claim 1 wherein the pharmaceutically acceptable salt is a methanesulfonate salt.
- 14/15. (Amended) The method of claim 1 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt.% of (S,S) reboxetine, and less than about 10 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claims 32-38 have been canceled, without prejudice.

New claims 63-76 have been added and are as follows:

- C<sup>3</sup>
- 19/63. The method of claim 39 wherein said composition is administered in an amount of about 0.5 to about 8 mg/day.
- 20/64. The method of claim 63 wherein said composition is administered in an amount of about 0.5 to about 5 mg/day.
- 21/65. The method of claim 64 wherein said composition is administered in an amount of about 0.5 to about 2.5 mg/day.
- 22/66. The method of claim 65 wherein said composition is administered in an amount of about 0.5 to about 0.9 mg/day.
- 23/67. The method of claim 66 wherein said composition is administered in an amount of about 0.5 to about 0.8 mg/day.
- 24/68. The method of claim 67 wherein said composition is administered in an amount of about 0.5 to about 0.75 mg/day.
- 25/69. The method of claim 68 wherein said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally.
- 26/70. The method of claim 69 wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the group consisting of a binder, diluent, lubricant, disintegrating agent, effervescent agent, dyestuff, sweetener, wetting agent, and mixtures thereof.

U.S. Serial No. 09/599,213

<sup>27</sup>  
21. The method of claim <sup>26</sup>70 wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

<sup>28</sup>  
22. The method of claim <sup>25</sup>69 wherein said composition is parenterally administered subcutaneously, intravenously, or intramuscularly.

<sup>29</sup>  
23. The method of claim <sup>12</sup>39 wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

<sup>30</sup>  
24. The method of claim <sup>17</sup>39 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt. % of (S,S) reboxetine, and less than about 10 wt. % of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

<sup>31</sup>  
25. The method of claim <sup>30</sup>74 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt. % of (S,S) reboxetine and less than about 3 wt. % of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

<sup>32</sup>  
26. The method of claim <sup>31</sup>75 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt. % of (S,S) reboxetine and less than about 1 wt. % of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.